康华生物
(300841)
| 流通市值：60.67亿 | | | 总市值：64.84亿 |
| 流通股本：1.22亿 | | | 总股本：1.30亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 884,662,834.85 | 538,353,610.55 | 172,451,817.58 | 1,165,000,864.15 |
| 营业总成本 | 638,998,861.42 | 373,656,732.19 | 140,114,140.64 | 895,140,732.6 |
| 其他经营收益 | | | | |
| 营业利润 | 248,789,865.62 | 159,017,146.65 | 29,678,844.43 | 259,870,340.92 |
| 利润总额 | 248,538,790.28 | 158,880,576.46 | 29,543,013.64 | 259,743,208.05 |
| 净利润 | 218,153,143.22 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 218,153,143.22 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 2,658,871,944.02 | 2,468,543,068.77 | 2,434,038,938.98 | 2,523,195,286.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,744,205,698.56 | 1,501,913,502.13 | 1,472,277,867.15 | 1,486,577,781.58 |
| 资产总计 | 4,403,077,642.58 | 3,970,456,570.9 | 3,906,316,806.13 | 4,009,773,067.75 |
| 流动负债: | | | | |
| 流动负债合计 | 358,119,415.26 | 322,682,247.36 | 308,545,613.34 | 439,320,635.58 |
| 非流动负债: | | | | |
| 非流动负债合计 | 113,752,481.08 | 34,138,740.33 | 32,948,043 | 32,992,699.85 |
| 负债合计 | 471,871,896.34 | 356,820,987.69 | 341,493,656.34 | 472,313,335.43 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,701,208,534.93 | 3,613,635,583.21 | 3,564,823,149.79 | 3,537,459,732.32 |
| 股东权益合计 | 3,931,205,746.24 | 3,613,635,583.21 | 3,564,823,149.79 | 3,537,459,732.32 |
| 负债和股东权益合计 | 4,403,077,642.58 | 3,970,456,570.9 | 3,906,316,806.13 | 4,009,773,067.75 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 942,615,683.42 | 574,986,473.47 | 256,380,689.1 | 1,297,220,894.23 |
| 经营活动现金流出小计 | 669,351,892.32 | 413,488,819.73 | 235,508,012.28 | 917,510,609.19 |
| 经营活动产生的现金流量净额 | 273,263,791.1 | 161,497,653.74 | 20,872,676.82 | 379,710,285.04 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,550,369,572.35 | 1,186,443,466.1 | 452,172,423.21 | 1,028,132,880.28 |
| 投资活动现金流出小计 | 2,458,553,635.51 | 1,989,158,391.78 | 1,000,568,041.22 | 880,785,928.9 |
| 投资活动产生的现金流量净额 | -908,184,063.16 | -802,714,925.68 | -548,395,618.01 | 147,346,951.38 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | 179,793,800 |
| 筹资活动现金流出小计 | 205,726,029.73 | 205,283,323.78 | 110,187,740.04 | 363,215,261.39 |
| 筹资活动产生的现金流量净额 | -205,726,029.73 | -205,283,323.78 | -110,187,740.04 | -183,421,461.39 |
| 汇率变动对现金及现金等价物的影响 | -37,818.87 | -28,086.65 | -14,104.09 | 43,743.3 |
| 现金及现金等价物净增加额 | -840,684,120.66 | -846,528,682.37 | -637,724,785.32 | 343,679,518.33 |
| 期末现金及现金等价物余额 | 302,708,688.04 | 296,864,126.33 | 505,668,023.38 | 1,143,392,808.7 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -846,528,682.37 | - | 343,679,518.33 |
最新报告期：2026-09-24| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中泰证券 | 祝嘉琦 | 2.16 | 2.56 | 2.77 | 2026-09-24 |
| 中信建投 | 汤然,刘若飞,王在存,袁清慧,贺菊颖 | 2.16 | 2.54 | 2.86 | 2026-08-25 |
| 西南证券 | 杜向阳 | 2.01 | 2.31 | 2.56 | 2026-08-18 |